Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study

被引：0
|
作者：
Antoinette MaassenVanDenBrink
Gisela M. Terwindt
Joshua M. Cohen
Steve Barash
Verena Ramirez Campos
Maja Galic
Xiaoping Ning
Mikko Kärppä
机构：
[1] Erasmus University Medical Center Rotterdam,Division of Pharmacology and Vascular Medicine, Department of Internal Medicine
[2] Leiden University Medical Center,Department of Neurology
[3] Teva Pharmaceutical Products R&D,Research Unit of Clinical Neuroscience
[4] Inc.,undefined
[5] Teva Pharmaceuticals Europe B.V.,undefined
[6] University of Oulu and Medical Research Center,undefined
[7] Oulu University Hospital,undefined
来源：
The Journal of Headache and Pain | 2021年 / 22卷
关键词：
Fremanezumab; Calcitonin gene-related peptide; Age; Sex; Migraine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 47 条
  • [31] Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials
    Shapiro, Robert E.
    Hochstetler, Helen M.
    Dennehy, Ellen B.
    Khanna, Rashna
    Doty, Erin Gautier
    Berg, Paul H.
    Starling, Amaal J.
    JOURNAL OF HEADACHE AND PAIN, 2019, 20 (01):
  • [32] Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials
    Robert E. Shapiro
    Helen M. Hochstetler
    Ellen B. Dennehy
    Rashna Khanna
    Erin Gautier Doty
    Paul H. Berg
    Amaal J. Starling
    The Journal of Headache and Pain, 2019, 20
  • [33] Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN)
    Ford, Janet
    Tassorelli, Cristina
    Leroux, Elizabeth
    Wang, Shufang
    Ayer, David
    Nichols, Russell
    Detke, Holland
    QUALITY OF LIFE RESEARCH, 2021, 30 (01) : 105 - 115
  • [34] Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN)
    Janet Ford
    Cristina Tassorelli
    Elizabeth Leroux
    Shufang Wang
    David Ayer
    Russell Nichols
    Holland Detke
    Quality of Life Research, 2021, 30 : 105 - 115
  • [35] Adding eptinezumab to brief patient education to treat chronic migraine and medication-overuse headache: Protocol for RESOLUTION-A phase 4, multinational, randomized, double-blind, placebo-controlled study
    Jensen, Rigmor H.
    Schytz, Henrik Winther
    Tassorelli, Cristina
    Terwindt, Gisela M.
    Carlsen, Louise N.
    Mittoux, Aurelia
    osterberg, Ole
    Lipton, Richard B.
    Tepper, Stewart J.
    Blumenfeld, Andrew
    Lundqvist, Christofer
    FRONTIERS IN NEUROLOGY, 2023, 14
  • [36] 100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies
    Rosen, Noah
    Pearlman, Eric
    Ruff, Dustin
    Day, Kathleen
    Nagy, Abraham Jim
    HEADACHE, 2018, 58 (09): : 1347 - 1357
  • [37] Novel design for a phase IIa placebo-controlled, double-blind randomized withdrawal study to evaluate the safety and efficacy of CNV1014802 in patients with trigeminal neuralgia
    Zakrzewska, Joanna M.
    Palmer, Joanne
    Ettlin, Dominik A.
    Obermann, Mark
    Giblin, Gerard M. P.
    Morisset, Valerie
    Tate, Simon
    Gunn, Kevin
    TRIALS, 2013, 14
  • [38] Efficacy and Safety of a Selective Estrogen Receptor β Agonist, ERB-041, in Patients With Rheumatoid Arthritis: A 12-Week, Randomized, Placebo-Controlled, Phase II Study
    Roman-Blas, Jorge A.
    Castaneda, Santos
    Cutolo, Maurizio
    Herrero-Beaumont, Gabriel
    ARTHRITIS CARE & RESEARCH, 2010, 62 (11) : 1588 - 1593
  • [39] Efficacy of almotriptan 12.5 mg in achieving migraine-related composite endpoints: a double-blind, randomized, placebo-controlled study in patients with previous poor response to sumatriptan 50 mg
    Diener, HC
    CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (10) : 1603 - 1610
  • [40] Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials)
    Ailani, Jessica
    Andrews, J. Scott
    Rettiganti, Mallikarjuna
    Nicholson, Robert A.
    JOURNAL OF HEADACHE AND PAIN, 2020, 21 (01):
12345